HK Stock Market Move | REMEGEN (09995) rose nearly 5% in early trading. Its application for the listing of TaiTaiXiPep for the treatment of IgA nephropathy has been accepted and included in priority review.

REMEGEN (09995) rose nearly 5% in early trading, rising 4.75% as of the time of writing, to HK$93.75, with a turnover of HK$226 million. In terms of news, REMEGEN announced that its independently developed innovative drug, Taimatsup (trade name: Tai'ai), which is a fusion protein targeting the BLyS/APRIL dual receptor for the treatment of primary IgA nephropathy, has had its listing application accepted by the National Medical Products Administration Drug Evaluation Center (CDE) and has been included in the priority review program. Taimatsup becomes the first domestically researched and developed new drug to apply for listing in the field of IgA nephropathy. Furthermore, on September 23, Taimatsup's overseas partner, VorBio, announced the appointment of Dr. Navid Z. Khan as CMO. Huatai pointed out that prior to joining, Dr. Khan had led the global development of innovative drugs such as agamode, accumulating extensive experience in the field of nervous and autoimmune diseases. With strong global competitiveness, Taimatsup has great potential for the treatment of MG and is the first innovative drug to be filed globally in the pSS field; combined with Dr. Khan's rich experience, the outlook for global development of Taimatsup is positive. A and H shares maintain a "buy" rating.